Q32 Bio Inc. (NASDAQ:QTTB) Receives $12.17 Consensus PT from Analysts

Shares of Q32 Bio Inc. (NASDAQ:QTTB) have earned an average recommendation of “Hold” from the eight analysts that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $12.17.

QTTB has been the topic of a number of research reports. Wells Fargo & Company lowered their price objective on Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 12th. Wall Street Zen upgraded shares of Q32 Bio from a “sell” rating to a “hold” rating in a research report on Friday.

Q32 Bio Trading Up 2.8%

Shares of Q32 Bio stock opened at $1.49 on Friday. Q32 Bio has a 1 year low of $1.38 and a 1 year high of $53.79. The company’s fifty day simple moving average is $1.69 and its 200-day simple moving average is $2.30. The company has a market cap of $18.18 million, a price-to-earnings ratio of -0.30 and a beta of -0.04. The company has a current ratio of 4.71, a quick ratio of 4.71 and a debt-to-equity ratio of 1.68.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.33. As a group, sell-side analysts expect that Q32 Bio will post -12.32 EPS for the current year.

Hedge Funds Weigh In On Q32 Bio

Several institutional investors have recently added to or reduced their stakes in QTTB. Public Employees Retirement System of Ohio bought a new position in shares of Q32 Bio in the fourth quarter valued at approximately $26,000. AXQ Capital LP bought a new position in shares of Q32 Bio in the fourth quarter valued at about $36,000. Raymond James Financial Inc. bought a new stake in shares of Q32 Bio during the fourth quarter valued at approximately $37,000. Cubist Systematic Strategies LLC bought a new position in Q32 Bio in the 4th quarter valued at $42,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Q32 Bio in the 4th quarter valued at $53,000. 31.32% of the stock is owned by institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.